近日，国际权威肿瘤学期刊《柳叶刀·肿瘤学》（The Lancet Oncology，影响因子35.9）在线发表了一项由上海市胸科医院韩宝慧教授和天津医科大学肿瘤医院李凯教授主导的“头对头”III期临床研究（CAMPASS）结果。该研究[1]证实，“得福组合”（贝莫苏拜单抗联合盐酸安罗替尼）一线治疗PD-L1阳性晚期非小细胞肺癌（NSCLC），无进展生存期（PFS）和客观缓解率（ORR）均优于“K药...
Source Link近日，国际权威肿瘤学期刊《柳叶刀·肿瘤学》（The Lancet Oncology，影响因子35.9）在线发表了一项由上海市胸科医院韩宝慧教授和天津医科大学肿瘤医院李凯教授主导的“头对头”III期临床研究（CAMPASS）结果。该研究[1]证实，“得福组合”（贝莫苏拜单抗联合盐酸安罗替尼）一线治疗PD-L1阳性晚期非小细胞肺癌（NSCLC），无进展生存期（PFS）和客观缓解率（ORR）均优于“K药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.